https://clinicaltrials.gov/ct2/show/NCT03154619 Abstract: The...

https://clinicaltrials.gov/ct2/show/NCT03154619

Abstract: The cost-effectiveness of a novel soluble beta-glucan gel.

RESULTS:

Over an annual budget cycle, SBG gel is expected to heal 94% of wounds compared with 78% when given standard care. It also healed wounds more quickly, with the average expected healed weeks 34.4 in the SBG gel group, compared with 24.7 methylcellulose dressing group. In our model this leads to a cost saving over an annual budget cycle of £503 per patient. Note: healed weeks refers to the number of weeks when the wound has healed during the 12-week period and should not be confused with weeks to healing.
CONCLUSION:

The shorter healing time associated with the SBG gel treatment leads to a cost saving because fewer weeks of treatment are required to heal the wound, suggesting this is a promising new cost-effective option for the treatment of DFUs.